Will serum lipid lowering treatment reduce the incidence of coronary heart disease?
The question whether serum lipid lowering treatment will reduce the incidence of coronary heart disease (CHD) has been a matter of intense debate during the last few years. When analysing the results from the major preventive trials, it can be concluded that there is no unequivocal evidence that lipid lowering treatment will reduce the death rate in CHD. However, the great majority of the trials performed have shown a reduced number of CHD deaths in the treatment group, compared with the control group. There is strong evidence that lipid lowering treatment of hyperlipidaemic patients will reduce the incidence of non-fatal myocardial infarctions. This reduction is directly proportional to the degree of cholesterol lowering achieved.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000097:blood / Q000401:mortality* / Q000517:prevention & control*; D004032:Diet; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use; D012306:Risk; D012907:Smoking
D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D002784:Cholesterol; D002994:Clofibrate